الرئيسية » أخبار (صفحة 3)

أخبار

Hypertension Medication Valsartan May Help Prevent Vaso-Occlusive Episodes in Sickle Cell Disease

A medication used to treat high blood pressure, called Valsartan, may help decrease the stickiness of red blood cells and reduce the risk of vaso-occlusive crisis in people with sickle cell disease (SCD), a research study suggests. The study, “Valsartan impedes epinephrine-induced ICAM-4 activation on normal, sickle cell trait and sickle cell ...

أكمل القراءة »

Cypriot Stella Kyriakides named EU Health Commissioner

Cypriot psychologist and politician to take over from Vytenis Andriukaitis on November 1 Stella Kyriakides has got the nod as EU Commissioner for Health, making her part of a strong female presence in the new structure of the next European Commission. Kyriakides, one of 13 women commissioners from 27, replaces ...

أكمل القراءة »

TIF releases new video on thalassaemia prevention

  Thalassaemia is a hereditary blood disease that CAN be prevented! But in what ways? ΤΙF’s latest educational video shines a spotlight on the essential aspect of the disease’s prevention, still challenging  in numerous countries across the world. Our goal? To further improve understanding and knowledge of the prevention’s vital ...

أكمل القراءة »

World Patient Safety Day – 17 September 2019

134 million adverse events occur each year due to unsafe care in hospitals in low- and middle-income countries, contributing to 2.6 million deaths annually! Safety in health systems is a major global concern due to the enlarging numbers of people suffering avoidable harm while receiving healthcare. Recognizing the urgency of ...

أكمل القراءة »

World Hepatitis Day 2019

World Hepatitis Day (WHD) takes places every year on 28 July bringing the world together under a single theme to raise awareness of the global burden of viral hepatitis and to influence real change. According to the World Health Organization (WHO), Viral hepatitis B and C affect 325 million people ...

أكمل القراءة »

FDA Accelerates Review Of Sickle Cell Disease Medicine Crizanlizumab

Novartis announced earlier today the FDA accepted the company’s Biologics License Application (BLA) and has granted Priority Review for its investigational Sickle Cell (SCD) medicine Crizanlizumab. If FDA-approved, crizanlizumab is expected to represent the first monoclonal antibody targeting the P-selectin mediated multi-cellular adhesion in sickle cell disease! Novartis submitted the application ...

أكمل القراءة »